Akinchan Bhardwaj: Exercise Biological Modifier of Vascular Trajectory
Akinchan Bhardwaj, Consultant Interventional Cardiologist at Kauvery Hospital, shared a post on LinkedIn:
“If exercise were a drug, we would call it multi-target vascular therapy.
Exercise is often framed as ‘cardiovascular risk reduction.’ But that description undersells what it actually does.
Exercise is not simply a statistical modifier of event probability.
It is a biological modifier of vascular trajectory.
Regular physical activity has been shown to:
- Improve endothelial nitric oxide bioavailability
- Reduce systemic inflammatory tone
- Enhance insulin sensitivity independent of weight loss
- Improve autonomic balance and blood pressure variability
- Influence plaque phenotype toward more stable morphology
Most pharmacologic therapies act on a single pathway.
Exercise simultaneously influences lipid metabolism, inflammation, metabolic pressure and vascular function.
If cardiovascular risk is a curve, exercise does not just shift it downward. It reduces its slope.
That distinction matters as we rethink prevention in an era of genomics, AI and precision risk modeling.
I explore this in my latest CardioForesight essay:
‘Exercise Doesn’t Just Lower Risk, It Changes Vascular Biology.'”
Stay updated with Hemostasis Today.
-
Apr 29, 2026, 07:12Matteo Foschi: Is There a Benefit to Switching DOACs After Breakthrough Stroke?
-
Apr 29, 2026, 07:02Enrico Ferro: Stroke Risk in PFA vs Radiofrequency Ablation
-
Apr 29, 2026, 06:03Proud to Recognize 6 Early Career Investigators as the Recipients of the 2026 JTH Editors’ Awards – JTH
-
Apr 29, 2026, 05:55On Hemophilia Care Advances, Collaboration and Access in India at IHC X 2026 – Hemophilia Federation India
-
Apr 29, 2026, 05:46Rajendra Tapadia: Strengthening Last-Mile Hemophilia Care Through Structured Community Outreach
-
Apr 29, 2026, 05:37Masoabi Sefojane: Whose Realities Shape Global Priorities in Hemophilia Care?
-
Apr 29, 2026, 05:24Filippo Cademartiri: Mandatory Reading for Anyone Who Mistakes Expertise for Certainty
-
Apr 29, 2026, 02:52Fengqian Chen: Another Reality Check for the Factor XI Inhibitor Race – Novartis’ Abelacimab Setback
-
Apr 29, 2026, 02:18Arnaud Baldivia: Peri-Procedural Stroke – An Underestimated Emergency in the Operating Room and in the ICU